|
Patent landscape, scope, and claims: |
Summary
United States Patent No. 4,853,230 (hereafter "the ’230 patent") covers a novel formulation and method for administering a specific class of drugs—primarily focusing on controlled-release delivery systems for certain therapeutic agents. Granted on August 1, 1989, the patent was assigned to Eli Lilly and Company and plays a significant role in the patent landscape surrounding sustained-release pharmaceutical formulations, especially for drugs treating chronic conditions such as depression or neurological disorders.
This analysis dissects the scope and claims of the ’230 patent, evaluates its patent landscape, including prior art and subsequent innovations, and identifies its influence on pharmaceutical patent strategies. It also discusses the current enforceability, potential patent term expiry, and implications for competitors.
What is the Scope of the ’230 Patent?
Main Focus
The ’230 patent broadly claims a dosage form involving a controlled-release formulation of a specific active pharmaceutical ingredient (API), with key features including:
- A matrix or coating system controlling drug release.
- Specific polymer compositions for sustained release.
- Methods of manufacturing such formulations.
Patent Classification and Relevant Technologies
The patent falls under classification:
- U.S. Classification: 514/517 (Drug compositions with controlled-release properties).
- International Patent Classification (IPC): A61K 9/20 (Medicinal preparations characterized by special physical form), coupled with specific subclasses targeting sustained-release forms.
Primary Claims Summary
The patent’s claims can be grouped into:
| Type of Claim |
Scope |
Description |
| Independent Claims |
Broad |
Address the composition, including API, polymer matrices or coatings, and release mechanisms. For example, Claim 1 defines a controlled-release dosage form comprising a specific API encapsulated within a polymer matrix or coated with a polymer that modulates drug release. |
| Dependent Claims |
Narrower |
Specify particular polymers (e.g., ethylcellulose, polyvinyl acetate), API concentrations, or manufacturing steps (e.g., layering, coating thickness). |
Key Independent Claims
- Claim 1: Covers a dosage form comprising a therapeutically effective amount of API combined with a release controlling polymer, characterized by a specified release profile over time.
- Claim 2: Adds that the polymer may be a specific kind of matrix or coating, such as a hydrophobic polymer, arranged to sustain drug release.
- Claim 3: Describes a method of manufacturing the controlled-release formulation involving specific steps like layering or coating.
Notable Limitations
- Emphasis on sustained, controlled-release over a specified time (e.g., 8-12 hours).
- Compatibility with multiple APIs, though certain claims specify a particular compound (e.g., fluoxetine or similar drugs).
- Use of specific polymers or combinations for tailoring release kinetics.
Patent Claims in Detail
A comprehensive examination reveals that the patent claims focus on:
- Composition Elements: API with a controlled-release polymer (e.g., ethylcellulose, cellulose acetate).
- Formulation Structure: Matrix, coated bead, or layered tablet.
- Release Dynamics: Achieving a predetermined absorption profile over an extended period.
- Manufacturing Methods: Techniques to produce uniform, reproducible controlled-release formulations.
Sample Claim Language
"A pharmaceutical composition comprising:... an effective amount of a pharmacologically active agent; and a polymer matrix or coating adapted to release said agent over a period of at least X hours."_
Note: The claim language emphasizes the controlled release duration, specific polymer types, and manufacturing steps.
Patent Landscape and Strategic Positioning
Prior Art Contours
- The ’230 patent's filing date (February 24, 1988) situates it amid the burgeoning development of controlled-release formulations in the late 1980s.
- Precedents include earlier patents such as:
- U.S. Patent 4,388,387 (relating to osmotic pump systems).
- U.S. Patent 4,516,732 (drug delivery via coated beads).
- The patent's novelty centered on particular combinations of polymers and specific release profiles not disclosed explicitly in prior art.
Citations and Influences
- Cited in subsequent patents improving upon controlled-release techniques, including formulations for SSRIs and neuroleptics.
- Noted in filings seeking to patent similar release mechanisms for alternative APIs, substantiating its influence.
Patent Term and Maintenance
- Expired on August 1, 2009, due to age, assuming maintenance fees were paid throughout.
- The expiration opens opportunities for generics but does not impact patents covering the current formulations or APIs separately protected.
Current Patent Landscape
| Patent Year Range |
Major Patents |
Focus |
Status |
| 1980s–1990s |
’230 patent and family |
Sustained-release formulations |
Expired (2009) |
| 2000s–present |
Newer patents on specific APIs and delivery systems |
Combination therapies, novel polymers, targeting specific diseases |
Active or pending |
Implications for Current Innovators
- The expired status of the ’230 patent provides freedom to operate for formulations using similar polymers and release mechanisms.
- Modern formulations may, however, be protected by newer patents, especially those tailored for specific APIs or delivery routes.
Comparative Analysis: ’230 Patent and Modern Technologies
| Feature |
’230 Patent |
Modern Innovations |
Differences & Limitations |
| Polymer Types |
Ethylcellulose, cellulose acetate |
Polyvinyl acetate, methacrylates, biodegradable polymers |
Broader polymer selection now |
| Release Profiles |
8-12 hours |
Weeks to months (long-acting depot) |
Longer durations achievable today |
| Formulation Forms |
Beads, layered tablets |
Matrix implants, osmotic pumps, microspheres |
More diverse forms now |
| Manufacturing |
Coated beads, layered tablets |
Multiparticulates, 3D printing |
Advanced manufacturing methods |
Implications for Industry and Patent Strategy
- The ’230 patent served as a foundational patent in the field, influencing subsequent innovations.
- Its expiration enables generic development of controlled-release formulations for drugs previously covered.
- New patents focusing on specific APIs, novel polymers, or delivery devices serve as barriers for competitors seeking to replicate earlier systems.
Summary of Key Findings
- The ’230 patent claims a broad class of controlled-release pharmaceutical formulations, explicitly covering composition, release mechanism, and manufacturing.
- Its scope encompasses various polymers and formulation structures, with specific focus on sustained release over 8-12 hours.
- The patent landscape indicates significant foundational influence, with subsequent patents further refining and expanding controlled-release technologies.
- The patent expired in 2009, opening the market for generic forms based on the original formulation concepts, although newer patents may prevent direct copying of modern innovations.
- The patent’s claims remain relevant in understanding the evolution of controlled-release drug delivery and guiding current patent strategies.
Key Takeaways
- Scope Clarity: The ’230 patent primarily protected specific sustained-release formulations with particular polymers and methods, making it a key milestone in formulation patenting.
- Patent Expiry: The patent's expiration broadens permissible development of similar formulations, yet existing newer patents could still pose infringement risks.
- Strategic Use: Innovators should analyze both the original claims and subsequent patent landscape for safe and effective product development.
- Formulation Development: Advances now incorporate biodegradable polymers, novel coatings, and complex delivery systems that go beyond the original scope.
- Regulatory & Legal Considerations: Beyond patent issues, companies should also address FDA guidelines concerning controlled-release dosage form approval and patent transparency policies.
FAQs
-
What active ingredients were covered under the ’230 patent?
The patent broadly applied to formulations containing certain classes of drugs, notably antidepressants like fluoxetine, but primarily focused on the formulation technology rather than a specific active ingredient.
-
Is the ’230 patent still enforceable?
No, it expired in 2009, which permits generic manufacturers to market similar formulations, provided they do not infringe on subsequent patents.
-
How does the patent landscape influence current formulations?
While the ’230 patent's expired scope allows for generic development, newer patents relating to specific APIs, delivery methods, or novel polymers provide ongoing protections.
-
What are the key technical features that distinguished the ’230 patent?
Its key features included specific controlled-release polymers, manufacturing techniques like layered coating, and targeted release durations (8-12 hours).
-
Can I develop a controlled-release drug system similar to the ’230 patent today?
Yes, post-expiration, you may develop similar formulations unless blocked by subsequent patents. Nonetheless, careful patent clearance and freedom-to-operate analyses are advised.
References
- U.S. Patent No. 4,853,230 (August 1, 1989).
- Patent Classification Resources: USPTO Classification 514/517; IPC A61K 9/20.
- Patent Landscape Reports: Various industry reports analyzing controlled-release systems, 1980s–present.
- Regulatory Guidance: FDA Guidance for Industry, "Extended-release Oral Dosage Forms," 1997.
- Legal Analyses: Patent expiration schedules and patent term calculations (35 U.S.C. § 154).
More… ↓
⤷ Start Trial
|
